MFN Drug Pricing Targets: Lowering U.S. Drug Co...

By Rene Pretorius

May 21, 2025

Summary The U.S. Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS) have set Most-Favored-Nation (MFN)
Drug Pricing Analysis: ICER’s Launch Price and Access Report Aims to En...
Trends in Anticancer Drug Pricing: Analyzing Medicare Launch Prices and Impac...
Canada Drug Agency Plan: Shaping the Future of Health Systems 2025-2030
Implementing Health Technology Assessment in Oman
Journavx for Pain Management: Toward Affordability and Access
Optimizing Value-Based Drug Pricing in Japan with MARIE Framework
Navigating Drug Price Regulation: Evaluating the Executive Order’s Pote...
Capivasertib Cost-Effectiveness in Advanced Breast Cancer
Advances in Colorectal Cancer Screening: Access and Cost
Journavx Market Access Strategy in Focus: What Early Payer Decisions Signal f...
Pharmacy Benefit Managers Report Reveals Escalating Drug Costs and Calls for ...
Tariff Impact on Drugs: Navigating Challenges in the Generic and Biosimilar M...